Graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS), disease-free survival (DFS), and overall survival (OS) by total dose of anti-thymocyte globulin (ATG) in the overall population (A–C), in subgroups with low/intermediate disease risk indices (DRI; D–F), and in subgroups with high/very high DRI (G–I).